Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

VIsual Pathways Model in Neuro-inflammatory Disorders

NCT05487989 ·Status: RECRUITING

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

NCT04869358 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder

NCT07182409 ·Status: NOT_YET_RECRUITING

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

NCT03551275 ·Status: COMPLETED ·Phase: PHASE1

A Study for Patients With Relapsing Remitting Multiple Sclerosis

NCT00869986 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

NCT01435993 ·Status: TERMINATED ·Phase: PHASE1

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

NCT00753792 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

NCT00079495 ·Status: COMPLETED ·Phase: PHASE2

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

NCT00988052 ·Status: TERMINATED ·Phase: PHASE3

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

NCT02809079 ·Status: UNKNOWN ·Phase: PHASE4

Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

NCT06561009 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

NCT04056897 ·Status: COMPLETED ·Phase: PHASE2

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

NCT05834855 ·Status: RECRUITING ·Phase: PHASE3

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

NCT05208840 ·Status: WITHDRAWN ·Phase: PHASE4

The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)

NCT02850705 ·Status: COMPLETED

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

NCT04843774 ·Status: COMPLETED

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349 ·Status: COMPLETED ·Phase: PHASE2

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

NCT01039103 ·Status: TERMINATED ·Phase: PHASE2

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401 ·Status: COMPLETED

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

NCT05385744 ·Status: COMPLETED ·Phase: PHASE3

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

NCT04837651 ·Status: COMPLETED

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

NCT05296161 ·Status: RECRUITING ·Phase: PHASE4

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359 ·Status: COMPLETED

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

NCT05121662 ·Status: COMPLETED

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

NCT04783935 ·Status: COMPLETED ·Phase: PHASE4